209 related articles for article (PubMed ID: 28881658)
1. Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy.
Young CS; Clarke KM; Kettyle LM; Thompson A; Mills KI
Oncotarget; 2017 Aug; 8(31):51429-51446. PubMed ID: 28881658
[TBL] [Abstract][Full Text] [Related]
2. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.
Fiskus W; Wang Y; Joshi R; Rao R; Yang Y; Chen J; Kolhe R; Balusu R; Eaton K; Lee P; Ustun C; Jillella A; Buser CA; Peiper S; Bhalla K
Clin Cancer Res; 2008 Oct; 14(19):6106-15. PubMed ID: 18829489
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells.
Abou Najem S; Khawaja G; Hodroj MH; Babikian P; Rizk S
Cells; 2019 Nov; 8(12):. PubMed ID: 31766421
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
6. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Fiskus W; Rao R; Fernandez P; Herger B; Yang Y; Chen J; Kolhe R; Mandawat A; Wang Y; Joshi R; Eaton K; Lee P; Atadja P; Peiper S; Bhalla K
Blood; 2008 Oct; 112(7):2896-905. PubMed ID: 18660379
[TBL] [Abstract][Full Text] [Related]
7. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
Billam M; Sobolewski MD; Davidson NE
Breast Cancer Res Treat; 2010 Apr; 120(3):581-92. PubMed ID: 19459041
[TBL] [Abstract][Full Text] [Related]
8. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
9. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
Pommert L; Schafer ES; Malvar J; Gossai N; Florendo E; Pulakanti K; Heimbruch K; Stelloh C; Chi YY; Sposto R; Rao S; Huynh VT; Brown P; Chang BH; Colace SI; Hermiston ML; Heym K; Hutchinson RJ; Kaplan JA; Mody R; O'Brien TA; Place AE; Shaw PH; Ziegler DS; Wayne A; Bhojwani D; Burke MJ
Am J Hematol; 2022 May; 97(5):613-622. PubMed ID: 35180323
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.
Salahuddin A; Ghanem H; Omran GA; Helmy MW
Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988
[TBL] [Abstract][Full Text] [Related]
11. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
Burke MJ; Lamba JK; Pounds S; Cao X; Ghodke-Puranik Y; Lindgren BR; Weigel BJ; Verneris MR; Miller JS
Am J Hematol; 2014 Sep; 89(9):889-95. PubMed ID: 24891274
[TBL] [Abstract][Full Text] [Related]
12. HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents' combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model.
Alcitepe İ; Salcin H; Karatekin İ; Kaymaz BT
Med Oncol; 2022 Oct; 39(12):257. PubMed ID: 36224430
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.
Valdez BC; Tang X; Li Y; Murray D; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2018 Nov; 67():49-59.e1. PubMed ID: 30102945
[TBL] [Abstract][Full Text] [Related]
14. Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
Janning M; Ben-Batalla I; Loges S
Expert Rev Hematol; 2015 Apr; 8(2):135-8. PubMed ID: 25578023
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
How J; Minden MD; Brian L; Chen EX; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Webster S; Degelder T; Haines P; Stayner LA; McGill S; Wang L; Piekarz R; Wong T; Siu LL; Espinoza-Delgado I; Holleran JL; Egorin MJ; Yee KW
Leuk Lymphoma; 2015; 56(10):2793-802. PubMed ID: 25682963
[TBL] [Abstract][Full Text] [Related]
16. Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.
Li K; Hu C; Mei C; Ren Z; Vera JC; Zhuang Z; Jin J; Tong H
J Transl Med; 2014 Jun; 12():167. PubMed ID: 24923330
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy.
Hay JF; Lappin K; Liberante F; Kettyle LM; Matchett KB; Thompson A; Mills KI
Oncotarget; 2017 Sep; 8(40):67891-67903. PubMed ID: 28978082
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia.
Becktell K; Houser K; Burke MJ
J Pediatr Hematol Oncol; 2019 Jan; 41(1):e38-e40. PubMed ID: 29668549
[TBL] [Abstract][Full Text] [Related]
19. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
20. Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium.
Schafer ES; Chao K; Stevens AM; Jo E; Hilsenbeck SG; Gossai NP; Doan A; Colace SI; Guinipero T; Otterson D; Kaplan JA; Hinson A; Pommert L; Wayne AS; Bhojwani D; Burke MJ
Pediatr Blood Cancer; 2022 Oct; 69(10):e29812. PubMed ID: 35726868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
